- Home
- ATNI vs LUNG Comparison
ATNI vs LUNG Comparison
Compare ATNI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNI
- LUNG
- Stock Information
- Founded
- ATNI 1987
- LUNG 1995
- Country
- ATNI United States
- LUNG United States
- Employees
- ATNI N/A
- LUNG N/A
- Industry
- ATNI Telecommunications Equipment
- LUNG Industrial Specialties
- Sector
- ATNI Telecommunications
- LUNG Health Care
- Exchange
- ATNI Nasdaq
- LUNG Nasdaq
- Market Cap
- ATNI 457.4M
- LUNG 248.0M
- IPO Year
- ATNI 1991
- LUNG 2020
- Fundamental
- Price
- ATNI $33.48
- LUNG $6.41
- Analyst Decision
- ATNI Strong Buy
- LUNG Strong Buy
- Analyst Count
- ATNI 2
- LUNG 7
- Target Price
- ATNI $31.00
- LUNG $13.71
- AVG Volume (30 Days)
- ATNI 64.8K
- LUNG 190.7K
- Earning Date
- ATNI 10-29-2024
- LUNG 10-30-2024
- Dividend Yield
- ATNI 2.92%
- LUNG N/A
- EPS Growth
- ATNI N/A
- LUNG N/A
- EPS
- ATNI N/A
- LUNG N/A
- Revenue
- ATNI $760,078,000.00
- LUNG $76,583,000.00
- Revenue This Year
- ATNI N/A
- LUNG $22.73
- Revenue Next Year
- ATNI $2.19
- LUNG $19.02
- P/E Ratio
- ATNI N/A
- LUNG N/A
- Revenue Growth
- ATNI 1.83
- LUNG 26.26
- 52 Week Low
- ATNI $18.20
- LUNG $5.46
- 52 Week High
- ATNI $39.88
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- ATNI 69.39
- LUNG 35.82
- Support Level
- ATNI $31.93
- LUNG $6.39
- Resistance Level
- ATNI $32.67
- LUNG $7.07
- Average True Range (ATR)
- ATNI 0.71
- LUNG 0.36
- MACD
- ATNI -0.08
- LUNG -0.11
- Stochastic Oscillator
- ATNI 97.64
- LUNG 1.20
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise US Telecom and International Telecom. The company earns revenue from its telecommunication services.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.